Therapie des invasiven Glioblastoms mittels intranasaler Applikation von Shuttle-Zellen als Transporter für onkolytische Adenoviren"

31.03.2020 bis 28.02.2022

The non-invasive intranasal administration (INA) of stem cells producing different anticancer agents or oncolytic viruses has been proven to target human glioblastoma (GBM), the most aggressive and invasively growing brain tumor. This study will develop a novel “Trojan horse” approach of treatment using INA of YB-1-dependent oncolytic adenovirus (OAV, XVir-N31)-producing cells to target invasively growing glioma. This approach allows for four principally new strategies in the therapy of GBM: (i) Non-invasive INA of cell therapeutics, (ii) Usage of differentiated cells as safer shuttle vehicles than stem cells that are currently used for INA, (iii) OAVs that also target therapy resistant glioma stem cells (GSC) or recurrent glioma cells as more efficacious and targeted anticancer therapeutics than the existing standard or suicide gene-based therapy approaches. (iv) Additionally, our Trojan horse shuttle cells will target those invaded glioma cells which are the main source of recurrence. This is of fundamental importance because these cells will not be hit by the glioma standard therapy (e.g. irradiation, TMZ-based chemotherapy or surgical resection), or by a direct intratumoral injection of OAVs.